Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CytoDyn nets $9.2mm via RDO

Executive Summary

CytoDyn Inc. (antibody therapies for HIV) netted $9.2mm through the registered direct offering of 13.33mm common shares at $0.75 (a 27% discount) to institutional investors. The company also issued five-year warrants to buy another 6.67mm shares exercisable at $1 each. Rodman & Renshaw was the placement agent. CytoDyn will use some of the proceeds for clinical trials of its candidates.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Private Investment in Public Equity

Related Companies